Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin

Documenti analoghi

• Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
  di: Jones, Robin L., et al.
  Pubblicazione: (2021)
• Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
  di: Monk, Bradley J., et al.
  Pubblicazione: (2020)
• Efficacy and Safety of Trabectedin or Dacarbazine in Patients with Advanced Uterine Leiomyosarcoma after Failure of Anthracycline-based Chemotherapy: Subgroup Analysis of a Phase 3, Randomized Clinical Trial
  di: Hensley, Martee L., et al.
  Pubblicazione: (2017)
• Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
  di: Demetri, George D., et al.
  Pubblicazione: (2016)
• Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
  di: Patel, Shreyaskumar, et al.
  Pubblicazione: (2019)